Novo Nordisk presented CagriSema EASD 2026 data showing changed brain responses to food cues, reduced ‘food noise’, less fat around abdominal organs and preliminary bone reassurance in adults with obesity or type 2 diabetes.
Novo presented COMPETE SWITCH CV real-world data at EASD 2026. Adults with type 2 diabetes who escalated from Ozempic 1 mg to 2 mg were associated with a 6% lower MACE risk than those who switched to Mounjaro.
Novo receives a positive CHMP opinion for once-weekly Sogroya® (somapacitan) to treat children with idiopathic short stature in Europe.
Novo has secured a positive CHMP opinion for FREHEMGO® (denecimig) to treat haemophilia A in adults and children, offering the first FVIIIa mimetic with once-monthly, bi-weekly, and weekly dosing options in a pre-filled pen.
Novo and Anthropic announced a September 16, 2026 collaboration pairing Claude Science with Novo’s R&D teams to tackle drug discovery challenges and strengthen AI-driven software engineering, with financial terms undisclosed.
The Novo Nordisk rebrand introduces the single ‘Novo’ brand name, a ‘Lasting Health Starts Now’ platform, and a new culture framework called The Novo Way, unveiled by CEO Mike Doustdar ahead of the company’s 21 September Capital Markets Day in London.
